Mark Matson

935 citations

25 papers · 577 indexed · h-index 10

Impact in

Transplantation top 10%
Surgery
- Lipoproteins and Cardiovascular Health

Papers in ⓘ

Transplantation 1
Neurology 2

Co-authors: Eric P. Cohen (1 shared paper)Blaire Cooke (2 shared papers)Adam J. Shaywitz (3 shared papers)Scott M. Wasserman (2 shared papers)Bing Gao (3 shared papers)Marc W. Retter (3 shared papers)Karen Smirnakis (2 shared papers)Clapton Dias (3 shared papers)
Journals: Journal of Clinical Oncology (3 papers)Antiviral Research (2 papers)Current Medical Research and Opinion (2 papers)The Journal of Clinical Pharmacology (2 papers)Human Vaccines & Immunotherapeutics (1 paper)
Partner nations: United States Sweden Japan

In The Last Decade

Mark Matson

25 papers receiving 560 citations

Peers

Countries citing papers authored by Mark Matson

Since Specialization

Citations

This map shows the geographic impact of Mark Matson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Matson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Matson more than expected).

Fields of papers citing papers by Mark Matson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Matson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Matson. The network helps show where Mark Matson may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Matson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Matson Line = papers co-authored together Mark Matson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels Journal of the American College of Cardiology ·Clapton Dias, Adam J. Shaywitz, Scott M. Wasserman, Brian P. Smith, Bing Gao, Dina Stolman, Caroline Crispino, Karen Smirnakis, Maurice G. Emery, Alexander Colbert, John P. Gibbs, Marc W. Retter, Blaire Cooke, Stephen T. Uy, Mark Matson, Evan A. Stein	2012	202
2	Acquired Cystic Kidney Disease Medicine ·Mark Matson, Eric P. Cohen	1990	155
3	Pharmacokinetics and Pharmacodynamics of MK‐5046, a Bombesin Receptor Subtype‐3 (BRS‐3) Agonist, in Healthy Patients The Journal of Clinical Pharmacology ·Marc L. Reitman, Victor Dishy, Allison Moreau, William S. Denney, Chengcheng Liu, Walter K. Kraft, Alex Mejia, Mark Matson, S. Aubrey Stoch, John A. Wagner, Eseng Lai	2011	38
4	Pharmacokinetics and Safety of FV-100, a Novel Oral Anti-Herpes Zoster Nucleoside Analogue, Administered in Single and Multiple Doses to Healthy Young Adult and Elderly Adult Volunteers Antimicrobial Agents and Chemotherapy ·Helen S. Pentikis, Mark Matson, George Atiee, Brian Boehlecke, Jeff Hutchins, Joseph M. Patti, Geoffrey Henson, Amy Morris	2011	33
5	Long-term Follow-up of 369 Diabetic Patients Undergoing Dialysis Archives of Internal Medicine ·Mark Matson	1988	23
6	Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects Clinical Pharmacology in Drug Development ·Ying Cao, Taiji Sawamoto, Udaya Valluri, Kathy Cho, Michaelene Lewand, Suzanne K. Swan, Kenneth C. Lasseter, Mark Matson, John Holman, James J. Keirns, Tong Zhu	2016	23
7	A short 2 week dose titration regimen reduces the severity of flu-like symptoms with initial interferon gamma-1b treatment Current Medical Research and Opinion ·John Devane, Mary Lane Martin, Mark Matson	2014	12
8	Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers The Journal of Immunology ·Nandita Bose, Nadine Ottoson, Xiaohong Qiu, Ben Harrison, Jamie Lowe, Mark Uhlik, Blaine Rathmann, Takashi Kangas, Lindsay Jordan, Kathleen Ertelt, Adria Bykowski Jonas, Richard M. Walsh, Anissa Chan, Ross B. Fulton, Steven Leonardo, Kathryn Fraser, Keith Gorden, Mark Matson, Jeremy R. Graff, Richard D. Huhn	2019	12
9	Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: a comparative phase 2/3 trial Human Vaccines & Immunotherapeutics ·Mark Matson, Eran Schenker, Michal Stein, Vladislava Zamfirova, Huy‐Binh Nguyen, Garrett E. Bergman	2019	12
10	460 A STUDY OF THE SAFETY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF INX-08189, A NUCLEOTIDE POLYMERASE INHIBITOR, IN HEALTHY SUBJECTS Journal of Hepatology ·Joseph M. Patti, Mark Matson, Brian Boehlecke, Abdourahmane Barry, E. Wenzel, Helen S. Pentikis, Jahangir Alam, Geoff W. Henson	2011	10
11	Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation Current Medical Research and Opinion ·Mark Matson, Thomas Zimmerman, Dianne Tuccillo, Yongqiang Tang, Aaron Deykin	2011	9
12	Abstract 10701: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of AMG145 Circulation ·Clapton Dias, Adam J. Shaywitz, Brian D. Smith, Maurice G. Emery, Bing Gao, John P. Gibbs, Bill Wishner, Dina Stolman, Caroline Crispino, Blaire Cook, Alex Colbert, Marc W. Retter, Ren Xu, Mark Matson	2011	8
13	Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta‐1a in subjects with normal or impaired renal function The Journal of Clinical Pharmacology ·Xiao Hu, Ali Seddighzadeh, Scott Stecher, Ying Zhu, Jaya Goyal, Mark Matson, Thomas Marbury, William B. Smith, Ivan Nestorov, Serena Hung	2014	8
14	Transplantation, hemodialysis, and continuous ambulatory peritoneal dialysis for end-stage renal disease in diabetic patients Journal of Diabetic Complications ·Stefan H. Jacobson, David S. Fryd, Lars‐Eric Lins, Mark Matson, David E.R. Sutherland, Carl M. Kjellstrand	1988	6
15	VDR in salivary gland homeostasis and cancer The Journal of Steroid Biochemistry and Molecular Biology ·Kara A. DeSantis, Samantha Robilotto, Mark Matson, Noor M. Kotb, Cathryn M. Lapierre, Zenab Minhas, Alana A. Leder, Khushbakht Abdul, Emily M. Facteau, JoEllen Welsh	2020	5
16	Immune characteristics correlating with HSV‐1 immune control and effect of squaric acid dibutyl ester on immune characteristics of subjects with frequent herpes labialis episodes Immunity Inflammation and Disease ·Hugh McTavish, Katherine W. Zerebiec, Jay C. Zeller, Laurie L. Shekels, Mark Matson, Betsy T. Kren	2019	5
17	First-in-Human Phase I Clinical Trial of the Adenosine A1R/A3R Agonist AST-004 in Healthy Subjects Stroke ·Laura Manna, Juan Hernandez, Dawn E. Hunt, G Lakner, Mark Matson, Russell B. Poe, William S. Korinek, Robert Lancey, Theodore E. Liston	2024	3
18	AMG 145, a Fully Human Monoclonal Antibody Against PCSK9, Reduces LDL-C in Healthy Volunteers and Patients on Stable Doses of Statins† Journal of clinical lipidology ·Adam J. Shaywitz, Clapton Dias, Brian P. Smith, Bing Gao, John P. Gibbs, Maurice G. Emery, Caroline Crispino, Ren Xu, Dina Stolman, Alexander Colbert, Marc W. Retter, Blaire Cooke, Stephen Uy, Karen Smirnakis, Scott M. Wasserman, Mark Matson, Evan A. Stein	2012	3
19	A Study of the Safety and Pharmacokinetics of Multiple Ascending Doses of FV-100 in Healthy Subjects Antiviral Research ·Mark Matson, Helen S. Pentikis, Brian Boehlecke, Eric Wenzel, Geoff W. Henson, Amy Morris	2009	2
20	AB0364 Pharmacokinetics, safety, and tolerability of asp015k, a novel janus kinase inhibitor, in healthy volunteers Annals of the Rheumatic Diseases ·Tong Zhu, T. Sawamoto, Udaya Valluri, Michaelene Lewand, Ying Cao, Suzanne K. Swan, Kenneth C. Lasseter, Mark Matson, John Holman, James J. Keirns	2013	2

About Mark Matson

Mark Matson is a scholar working on Transplantation, Neurology, Endocrinology, Diabetes and Metabolism, Dermatology and Physiology, having authored 25 papers that have together received 577 indexed citations. Recurring topics across this work include Neuropeptides and Animal Physiology (2 papers), Cytokine Signaling Pathways and Interactions (2 papers), Chronic Lymphocytic Leukemia Research (2 papers), Diabetes Treatment and Management (2 papers), Antifungal resistance and susceptibility (2 papers), Polyomavirus and related diseases (2 papers), Lipoproteins and Cardiovascular Health (2 papers) and Neurological and metabolic disorders (2 papers). The work is most often cited by research in Transplantation (19 citations), Surgery (230 citations), Nephrology (36 citations), Pulmonary and Respiratory Medicine (112 citations) and Genetics (93 citations). Mark Matson has collaborated with scholars based in United States, Sweden and Japan. Frequent co-authors include Eric P. Cohen, Blaire Cooke, Adam J. Shaywitz, Scott M. Wasserman, Bing Gao, Marc W. Retter, Karen Smirnakis, Clapton Dias, Brian P. Smith and Evan A. Stein. Their work appears in journals such as Journal of Clinical Oncology, Antiviral Research, Current Medical Research and Opinion, The Journal of Clinical Pharmacology and Human Vaccines & Immunotherapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact